Department of Biochemistry, University of Madras, Guindy Campus, Chennai 600 025, Tamil Nadu, India.
Chem Biol Interact. 2012 May 30;197(2-3):119-28. doi: 10.1016/j.cbi.2012.04.005. Epub 2012 Apr 21.
This study mainly focuses on cardio protective anti-fibrotic activity of aminoguanidine against streptozotocin induced cardiac fibrosis and high glucose induced collagen accumulation in cardiac fibroblasts. Dysregulation of matrix metalloproteinase especially 2 and 9 were considered to be responsible for the abnormal collagen deposition, which resulting improper cardiac contractile function in diabetic mice. Mice received a single dose of streptozotocin (100 mg/kg) through tail vein to induce diabetes. Normal and diabetic mice received aminoguanidine orally (100 mg/kg/day) throughout the study period of 8 weeks. Cardiac fibroblasts cultured and exposed to high glucose, aminoguanidine and both for 48 h. Collagen quantitatively estimated in both in vivo and in vitro models. Altered structural changes were studied using the Masson tri-chrome staining, TEM images of cardiac sections. Increased collagen and metalloproteinase activities were confirmed using gelatin zymography, western blotting and gene expression studies. The exact mechanism responsible for high glucose induced collagen up regulation in diabetic heart was incompletely understood. From this above in vivo and in vitro results, we conclude that, the cardio protective anti fibrotic activity of amino guanidine was mainly attributed by exhibiting the inhibitory efficacy against streptozotocin and high glucose induced collagen accumulation probably by inhibiting high glucose altered metalloproteinase-2 and -9 activities.
本研究主要关注氨基胍对链脲佐菌素诱导的心脏纤维化和高糖诱导的心肌成纤维细胞胶原积累的心脏保护抗纤维化作用。基质金属蛋白酶(MMPs)的失调,特别是 MMP-2 和 MMP-9,被认为是导致糖尿病小鼠异常胶原沉积的原因,从而导致心脏收缩功能异常。通过尾静脉给予小鼠单次链脲佐菌素(100mg/kg)诱导糖尿病。正常和糖尿病小鼠在整个 8 周的研究期间每天口服氨基胍(100mg/kg)。将培养的和暴露于高糖、氨基胍和两者 48 小时的心肌成纤维细胞用于体内和体外模型的胶原定量评估。使用 Masson 三色染色、心脏切片的 TEM 图像研究结构变化。使用明胶酶谱、Western 印迹和基因表达研究证实了胶原和金属蛋白酶活性的改变。高血糖诱导糖尿病心脏胶原上调的确切机制尚不完全清楚。根据上述体内和体外结果,我们得出结论,氨基胍的心脏保护抗纤维化活性主要归因于其对链脲佐菌素和高糖诱导的胶原积累的抑制作用,可能是通过抑制高糖改变的 MMP-2 和 MMP-9 活性。